Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia.
Qiuhe JiLinong JiYi-Ming MuJiajun ZhaoBernard ZinmanChristoph WannerJyothis T GeorgeIsabella ZwienerKohjiro UekiKoutaro YokoteWataru OgawaOdd Erik JohansenPublished in: Diabetes, obesity & metabolism (2021)
Empagliflozin reduced cardiorenal and mortality risk regardless of BMI at baseline, including in Asians with a lower BMI.